Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.

Current opinion in pulmonary medicine - 1 Jan 2018

Parulekar Amit D, Kao Christina C, Diamant Zuzana, Hanania Nicola A

Abstract excerpt

PURPOSE OF REVIEW: Severe asthma is a heterogeneous disease that can be classified into phenotypes and endotypes based upon clinical or biological characteristics. Interleukin (IL)-4 and IL-13 play a key role in type 2 (T2) asthma. This article reviews the signaling pathway of IL-4 and IL-13 and highlights its targeted therapy in severe asthma. RECENT FINDINGS: Several clinical trials of biologics targeting the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Asthmatic Agents
Share to Asthma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inflammation

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Receptors, Interleukin-4

Share to Severity of Illness Index

Share to Th2 Cells

Source

Identifiers

PMID: 29036019
DOI: 10.1097/MCP.0000000000000436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.PMID 29036019Read ↗

IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies.Semantic proximity Read ↗

Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic FrontiersSemantic proximity Read ↗

T2-"Low" Asthma: Overview and Management Strategies.Semantic proximity Read ↗

Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes.Semantic proximity Read ↗

Biologic Therapy and Novel Molecular Targets of Severe Asthma.Semantic proximity Read ↗

What goes up must come down: biomarkers and novel biologicals in severe asthma.Semantic proximity Read ↗

New perspectives on the regulation of type II inflammation in asthmaSemantic proximity Read ↗

Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted ApproachSemantic proximity Read ↗

Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies.Semantic proximity Read ↗

Controversies and opportunities in severe asthma.Semantic proximity Read ↗

IL-4 and IL-13: Their Pathological Roles in Allergic Diseases and their Potential in Developing New TherapiesSemantic proximity Read ↗

Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.